Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA warns public of fraudulent stem cell schemes

This article was originally published in Scrip

Executive Summary

US regulators warned consumers about fraudsters peddling potentially dangerous and ineffective stem cell treatments, noting that only one stem cell product is approved by the US FDA – Hemacord, a hematopoietic progenitor cell product derived from cord blood, which is manufactured by the New York Blood Center and used for specified indications in patients with disorders affecting the body’s blood-forming system.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015841

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel